Schall Law Firm Invites Investors to Join Class Action Against Soleno Therapeutics for Fraud

Investors Urged to Lead Class Action Against Soleno Therapeutics

The Schall Law Firm has issued a reminder to investors regarding a critical class action lawsuit against Soleno Therapeutics, Inc. The lawsuit, which targets alleged violations of the Securities Exchange Act of 1934, particularly Sections 10(b) and 20(a), focuses on the misleading statements made by the Company concerning its product's safety during a key clinical trial. Investors who purchased Soleno’s securities between March 26, 2025, and November 4, 2025, are encouraged to get involved before the May 5, 2026 deadline.

Background of the Case

Soleno Therapeutics has been under scrutiny due to claims that it downplayed significant safety concerns related to its Phase 3 clinical trial surrounding the diazoxide choline extended-release tablets, also referred to as DCCR. According to reports, the Company failed to sufficiently disclose the safety risks associated with DCCR, which were more alarming than previously indicated. Furthermore, concerns were raised about the commercial viability of the product, coupled with the heightened risk of adverse events.

The complaint brought forward by investors illustrates a pattern of false and misleading statements directed at the market, which ultimately misled investors about the product’s safety profile. These revelations led to substantial financial loss when the truth about Soleno's claims became public.

Take Action

If you believe you've experienced losses due to investments in Soleno, it’s crucial to connect with the Schall Law Firm. Brian Schall, the attorney handling the case, offers consultations at no charge and invites investors to reach out via phone at 310-301-3335, or through their website at www.schallfirm.com. As of now, the class has not yet been certified, meaning that until that occurs, investors are not yet represented. Investors can take action to ensure they align themselves with this class.

What It Means for Investors

Being part of a class action lawsuit can provide significant leverage in recovering losses sustained from investments intertwined with potential fraud. By joining this lawsuit, investors stand to potentially reclaim damages resulting from the alleged misconduct by Soleno Therapeutics.

The Schall Law Firm has a history of representing shareholders globally, particularly in cases of securities fraud. With a commitment to protecting investor rights and navigating the complexities of class action litigation, they are equipped to advocate effectively on behalf of affected investors.

Investors need to act promptly to ensure their case is heard and to protect their interests against securities fraud. As the market continuously evolves, maintaining awareness of such legal opportunities can be essential for every investor.

In conclusion, if you are among those who invested in Soleno Therapeutics during the specified timeframe, consider stepping forward to join the class action. Understanding your rights as an investor is vital, and the Schall Law Firm is ready to assist you in reclaiming your losses effectively. Make sure to reach out before the deadline to ensure your rights are preserved.